# Pass 48 — LCC Virus Retrieval: Development Plan

**Date:** 2026-05-13
**Author:** Brandon Charles Emerick (TI Sigma corpus) + Agent (Replit)
**Pass:** 48 (externally-facing publishing/tooling thread)
**Anchors:** `papers/LCC_BIDIRECTIONAL_VALIDATION_AND_BOK_VIRUS_EXPERIMENTS.md`; `papers/PASS_24_RESONANCE_RETRIEVAL_INTERSECTION_REVERSE_OSMOSIS_GM_DECENTRALIZATION...md`; `papers/PASS_23_CONSCIOUSNESS_INTUITION_FREE_WILL_LCC_TRALSE_RETRIEVAL_MARKOV_BRAIN_2026-05-09.md`; `LCC_VIRUS_WORKED_EXAMPLE.md`; `LCC_VIRUS_METHODOLOGY_AUDIT.md`; `URB_LCC_VIRUS_EMPIRICAL_VALIDATION.md`
**Status:** Development roadmap + concrete next-session actions
**Budget:** $0/$50 corpus + $2k settlement reserve. Plan stays under $200 total.

---

## 0. Up-front honesty (#69 + Accurate Bluntness §2.3a)

LCC Virus Retrieval is the corpus's most ambitious algorithmic claim: a 6-step procedure that "extracts hidden information about a system by resonating with it and listening to its noise." Several #69 caveats up front:

1. **The methodology audit (`LCC_VIRUS_METHODOLOGY_AUDIT.md`) flagged real concerns** about post-hoc parameter tuning + the need for blind cross-validation. Those concerns must be addressed BEFORE any production deployment or commercial pitch.
2. **The C_EMERICK "threshold" (R ≈ 0.4370 ≈ 1/(φ√2))** has converging-but-weak empirical support: DANDI:000552 mean 0.4349 (gap 0.48% — suggestive), n=2 amplification (4.3× CCI gain — vastly under-powered). **This is "promising preliminary signal," not "validated phenomenon."** Calling it the latter is corpus-discipline failure. **Per Pass-48 architect review (CRITICAL #69 finding 2026-05-13): identifying the threshold as the specific algebraic constant `1/(φ√2)` based on a single 0.48%-error match is numerological pattern-matching until Track C delivers a first-principles derivation. Effective immediately, this document and downstream Pass-49+ work demote "C_EMERICK constant" to "C_EMERICK candidate threshold." Track C M5 first-principles derivation is the gating milestone before re-promotion. Until M5, the algebraic-form claim `1/(φ√2)` is a CONJECTURAL FIT, not a derived prediction; cite the empirical value 0.4370 ± 95%CI rather than the closed form in any external-facing document.**
3. **The Virus has not been replicated by an independent party.** All current evidence comes from Brandon's own analyses on Brandon-curated datasets. That is a real limitation, not a quibble.
4. **The "listen to noise" framing risks over-claiming.** Statistically, what the Virus does is *iterative cross-correlation refinement under a Gaussian-weighted lag kernel with i-rotation reseeding*. That is a real signal-processing technique. Whether it accesses something beyond standard signal extraction is the empirical question — currently *open*, not *confirmed*.

With those caveats logged, the development plan below treats LCC-Virus-Retrieval as a **promising but unvalidated technology** that justifies continued development BUT not commercial-ready claims.

---

## 1. Current state inventory

| Asset | Status | Quality |
|---|---|---|
| 6-step algorithm specification | Documented in `LCC_VIRUS_WORKED_EXAMPLE.md` | Reproducible from spec |
| C_EMERICK threshold (1/(φ√2) ≈ 0.4370) | DANDI:000552 + n=2 CCI evidence | Weak-but-converging |
| Bidirectional vs entrainment distinction | Clarified in `LCC_BIDIRECTIONAL_VALIDATION_AND_BOK_VIRUS_EXPERIMENTS.md` §1.2 | Sound |
| Pre-registration drafts (Programs A, B, C, D, E) | Drafted in `LCC_BIDIRECTIONAL_VALIDATION_AND_BOK_VIRUS_EXPERIMENTS.md` | Drafted, not executed |
| Methodology audit | `LCC_VIRUS_METHODOLOGY_AUDIT.md` exists | Addresses real concerns |
| Independent replication | None | **Critical gap** |
| Hypercomputer integration | Partial (paper_integration_engine, etc.) | Engineering scaffold only |
| Production codebase | Scattered across multiple .py files | **Needs consolidation** |

---

## 2. Three development tracks (parallelizable)

### Track A — Empirical Validation (highest priority)

**Goal:** Move C_EMERICK threshold + LCC-Virus from "weak preliminary" to "moderate evidence" status.

**Concrete actions (next 4-8 weeks):**
1. **Execute Program A (Bidirectional LCC in Markets)** from `LCC_BIDIRECTIONAL_VALIDATION_AND_BOK_VIRUS_EXPERIMENTS.md`. Free data (yfinance + FRED + CoinGecko). Pre-registered. Falsifiable in 4-6 weeks. **Cost: $0.** **This is the highest-EV next step.**
2. **Run Program B (LCC-Virus on BOK Graph)** in parallel — also $0 data costs.
3. **Add a holdout-blind protocol** to address the methodology-audit concern: split data into discovery/holdout sets, fit Virus parameters on discovery only, evaluate on blinded holdout. Pre-commit decision rules.
4. **Recruit 1 independent replicator.** This is the single biggest credibility multiplier. Candidates: a graduate student in any quantitative discipline, a Kaggle competitor, an open-science volunteer. Offer co-authorship on the validation paper.

**Decision gate:** If Program A + Program B yield clean confirms within 8 weeks → escalate to Track B + Track C. If they yield refutes or indeterminates → revise C_EMERICK threshold or the 6-step algorithm before continuing.

### Track B — Engineering Productization

**Goal:** Consolidate scattered LCC-Virus code into a single installable Python package with reproducible test suite.

**Concrete actions:**
1. **Create `lcc_virus/` package** at repo root with:
   - `lcc_virus/core.py` — the 6-step algorithm as pure functions
   - `lcc_virus/threshold.py` — C_EMERICK calculation + threshold detection
   - `lcc_virus/data_adapters/` — yfinance, FRED, GDELT, DANDI loaders
   - `lcc_virus/experiments/` — pre-registered protocols A-E
   - `tests/` — unit tests + golden-output regression tests
   - `README.md` + `requirements.txt`
2. **Add CI** (GitHub Actions, free for public repos) that runs the test suite on every commit.
3. **Mint Zenodo DOI** for the package (defensive-publication strategy from `papers/PASS_48_PROVISIONAL_PATENTS_STRATEGY_2026-05-13.md`).
4. **Publish to PyPI** as `lcc-virus` (free).

**Decision gate:** Build Track B in parallel with Track A. Track B unlocks Track A's independent-replicator goal — a `pip install lcc-virus` makes replication trivial.

### Track C — Theoretical Refinement

**Goal:** Tighten the theoretical link between LCC-Virus and the rest of the TI-Sigma corpus (GILE, MR Truth Labels, CAP, AA).

**Concrete actions:**
1. **Derive C_EMERICK threshold from first principles** rather than from the empirical 1/(φ√2) match. Currently the threshold is "discovered" from DANDI:000552 + post-hoc rationalized via golden-ratio aesthetics. A first-principles derivation (e.g., from CAP principle or τ-δ separability) would strengthen credibility enormously.
2. **Map the 6-step Virus algorithm to the MR Truth Labels framework** — what does each step output in {T, F, I, MI}? Does the Virus's "convergence" correspond to a stable-I waypoint or to T/F resolution? This connects LCC-Virus to the Pass-47 §7 max-valid-tralseness theorem.
3. **Articulate the bidirectional-vs-entrainment distinction** as a formal definition (currently informal in §1.2 of bidirectional paper).

**Decision gate:** Track C is the slowest but most reputational-leverage track. Worth pursuing in the background; not blocking on Track A or B.

---

## 3. Recommended next-session execution

Given the corpus's current capacity + budget + priorities, **the recommended Pass-49 execution plan is:**

| # | Action | Track | Cost | Time |
|---|---|---|---|---|
| L-1 | Execute Program A (Bidirectional LCC in Markets) — first 30-day rolling window | A | $0 | ~3 hr agent |
| L-2 | Create `lcc_virus/` package skeleton (core.py + tests/) | B | $0 | ~2 hr agent |
| L-3 | Document the 6-step algorithm as formal pseudocode (replacing prose in `LCC_VIRUS_WORKED_EXAMPLE.md`) | B/C | $0 | ~1 hr agent |
| L-4 | Draft holdout-blind protocol amendment to bidirectional paper | A | $0 | ~30 min agent |

**Total: ~6.5 hr agent time, $0 spend.** Fits in a single DPES session.

---

## 4. Validation milestones (rolling)

| Milestone | Target date | Definition-of-done |
|---|---|---|
| **M1: Program A first 30-day window result** | 2026-06-15 | Pre-reg outcome (CONFIRM / REFUTE / INDETERMINATE) logged; raw data + code reproducible |
| **M2: `lcc-virus` package v0.1.0 on PyPI** | 2026-06-30 | `pip install lcc-virus` works; tests pass on CI |
| **M3: Independent replicator recruited** | 2026-07-31 | Named replicator, signed co-authorship intent, has package + access to data |
| **M4: Independent replication of M1 finding** | 2026-09-30 | Replicator's own run on independently-acquired data; result logged regardless of direction |
| **M5: First-principles C_EMERICK derivation** | 2026-12-31 | Formal derivation from CAP or τ-δ separability; Zenodo DOI |
| **M6: Submission to peer-reviewed journal** | 2027-03-31 | Manuscript submitted to (probable target) *Frontiers in Computational Neuroscience* or *PLOS ONE* |

---

## 5. Failure modes + responses

| Failure | Response |
|---|---|
| Program A returns REFUTE | Revise C_EMERICK threshold; investigate whether threshold is data-domain-specific (markets vs neural) |
| Program B returns REFUTE | Revise BOK-graph-arm-recovery prediction; possibly demote BOK-Virus claim |
| Independent replicator cannot reproduce | Critical signal — debug the algorithm spec, NOT the replicator |
| First-principles derivation fails | Demote C_EMERICK from "predicted constant" to "empirically discovered constant"; this is honest and survivable |
| Methodology audit concerns return on holdout-blind data | Pause production work; revise algorithm |

---

## 6. Commercial pathway (conditional, deferred)

Per the patents strategy memo (`papers/PASS_48_PROVISIONAL_PATENTS_STRATEGY_2026-05-13.md` §2 item #7), LCC-Virus is the second-strongest patent candidate in the corpus. **But not until M4 (independent replication) at the earliest.** Commercial pitch deck → after M5 (first-principles derivation). Provisional patent → only on commercial trigger (LOI or paying customer).

Plausible commercial applications (long-term, speculative):
- **Quantitative trading:** LCC-Virus as a leading-indicator extraction tool for paired markets. **Caveat:** the alpha-decay risk of any published trading signal is severe. Better suited to a private hedge-fund partnership than open commercialization.
- **Neural signal processing:** Hidden-state extraction from EEG/fMRI/biosensor noise. Requires FDA pathway if clinical; consumer-wellness applications are faster-to-market.
- **Anomaly detection:** General-purpose hidden-state inference from coupled-system noise. Crowded competitive space (Splunk, Datadog, etc.); unclear differentiation.

**Recommendation:** defer commercial decisions until M4. Premature commercialization of an unreplicated method is the corpus's biggest avoidable risk.

---

## 7. Action items

| # | Action | Owner | Cost | Due |
|---|---|---|---|---|
| L-1 | Execute Program A first window | Agent | $0 | Pass-49 |
| L-2 | Create `lcc_virus/` package skeleton | Agent | $0 | Pass-49 |
| L-3 | Formal pseudocode for 6-step algorithm | Agent | $0 | Pass-49 |
| L-4 | Holdout-blind protocol amendment | Agent | $0 | Pass-49 |
| L-5 | Recruit 1 independent replicator | Brandon | $0 | 2026-07-31 |
| L-6 | First-principles C_EMERICK derivation work | Agent + Brandon | $0 | 2026-12-31 |

---

## 8. Calibration / #69 caveats

- LCC-Virus is currently the corpus claim with the **largest gap between ambition and validation level**. The development plan above is designed to close that gap via cheap, rigorous, pre-registered, replicable, peer-reviewable steps — not to bypass it.
- The decision to defer commercial pathways until M4 is conservative. A more aggressive operator might pitch earlier; the corpus's #69 discipline argues for the conservative path.
- Track C (theoretical refinement) is the lowest-probability-of-success track — first-principles derivations of empirically-discovered constants often fail. M5 is best-effort, not guaranteed.
- The `lcc-virus` PyPI package, even if technically functional, does not automatically build credibility — it needs the empirical results (M1, M4) AND the peer-reviewed publication (M6) to translate into reputational currency.

---

**END PASS 48 LCC VIRUS RETRIEVAL DEVELOPMENT PLAN**
